
Sonnet BioTherapeutics Holdings, Inc. (SONN) is a clinical-stage oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bispecific action. The company’s lead candidate is SON-1010, a fully human version of interleukin 12 for treating non-small cell lung and head and neck cancer.
In addition, the company is developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy.